GlassScriptPhysician profile
Eugene P Hunt
NPI 1376525329
$3,376.65
in general payments reported to CMS, 2019-2025
14 companies · $983 in 2025
The $983 reported for 2025 was more than what 90% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $256 · 2020: $41.50 · 2021: $98.65 · 2022: $27.37 · 2023: $85.02 · 2024: $1,885 · 2025: $983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,600 · Food and Beverage: $313 · Education: $39.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,600.00 |
| Food and Beverage | $313.31 |
| Education | $39.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $2,600.00 | 2024-2025 | Bovine Collagen |
| Therapeuticsmd, INC. | $286.94 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $123.99 | 2023-2025 | |
| Millicent US INC | $105.08 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Abbvie INC. | $61.99 | 2019-2022 | |
| Fisher Scientific Company L.L.C. | $39.49 | 2024 | Procalcitonin |
| Innovation Technologies INC | $27.94 | 2023 | Irrisept |
| Myriad Women'S Health, INC. | $26.69 | 2023 | Myrisk |
| Allergan, INC. | $24.37 | 2019 | |
| Merck Sharp & Dohme LLC | $18.72 | 2019 | |
| Duchesnay USA Incorporated | $17.52 | 2019 | |
| Aspira Women'S Health INC | $15.41 | 2023 | Ova1 |
| Agile Therapeutics, INC. | $14.31 | 2021 | |
| Astellas Pharma US INC | $14.20 | 2024 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Hunt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.